» Articles » PMID: 32182949

Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?

Abstract

Curative radiotherapy for prostate cancer is common in the elderly. However, concerns about potential toxicity have inhibited access to radiotherapy for this population, for whom preserving quality of life (QoL) is crucial. The primary endpoint was to identify predictors of impaired QoL in men aged 75 years or older treated with curative intent radiotherapy with or without androgen deprivation therapy (ADT) for localized prostate cancer. We prospectively performed comprehensive geriatric assessment (CGA) and administered QoL questionnaires to 208 elderly (>75 years) patients prior to, plus two and six months after, radiotherapy (NCT02876237). The median age of the patients was 77 years (range 75-89). At the start of the study, comorbidities were highlighted in 65% of patients: 23% were depressed, 23% had cognitive impairment, and 16% had reduced independence. At six months, 9% of patients had a consistently decreased QoL (>20 points), and a further 16% had a more moderate reduction (10 to 20 points) in QoL. None of the parameters studied (tumor characteristic, treatment, or oncogeriatric parameters) were predictive of a reduced QoL following radiotherapy. Though co-existing geriatric impairment was common, QoL was maintained for 75% of patients six months after radiotherapy. CGA was poorly predictive of tolerance of prostatic radiotherapy. Geriatric assessments dedicated to quality of life following radiotherapy need to be developed.

Citing Articles

Retrospective study on the toxicity induced by stereotactic body radiotherapy: overview of the reunion experience on prostate cancer in elderly patients.

Slama Y, Baumont G, Arcambal A, Begue M, Maillot O, Sayah R Front Oncol. 2024; 14:1302001.

PMID: 38361775 PMC: 10867626. DOI: 10.3389/fonc.2024.1302001.


High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.

Marotte D, Gal J, Schiappa R, Gautier M, Boulahssass R, Chand-Fouche M Clin Transl Radiat Oncol. 2022; 35:104-109.

PMID: 35692263 PMC: 9184865. DOI: 10.1016/j.ctro.2022.05.001.


Irradiation of localized prostate cancer in the elderly: A systematic literature review.

Marotte D, Chand-Fouche M, Boulahssass R, Hannoun-Levi J Clin Transl Radiat Oncol. 2022; 35:1-8.

PMID: 35492872 PMC: 9046879. DOI: 10.1016/j.ctro.2022.04.006.

References
1.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16(1):139-44. DOI: 10.1200/JCO.1998.16.1.139. View

2.
Longobardi B, Berardi G, Fiorino C, Alongi F, Cozzarini C, Deli A . Anatomical and clinical predictors of acute bowel toxicity in whole pelvis irradiation for prostate cancer with Tomotherapy. Radiother Oncol. 2011; 101(3):460-4. DOI: 10.1016/j.radonc.2011.07.014. View

3.
Bratt O, Folkvaljon Y, Eriksson M, Akre O, Carlsson S, Drevin L . Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. Eur Urol. 2015; 68(1):53-8. DOI: 10.1016/j.eururo.2014.12.026. View

4.
Alibhai S, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I . Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 2010; 28(34):5038-45. DOI: 10.1200/JCO.2010.29.8091. View

5.
Soubeyran P, Fonck M, Blanc-Bisson C, Blanc J, Ceccaldi J, Mertens C . Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012; 30(15):1829-34. DOI: 10.1200/JCO.2011.35.7442. View